We found that peptide F393–403 was able to inhibit FOXP3:NFAT interaction and demonstrated that in vivo peptide administration had antitumor activity in a murine model of hepatocellular carcinoma [12]. This evidence concerns the gene FOXP3 and hepatocellular carcinoma.